This post was originally published on this site The U.S. label of Nerlynx (neratinib), a treatment for early stage HER2-positive breast cancer, now includes information on the use of two anti-diarrheal medications to prevent severe side effects of the therapy. Puma Biotechnology, which markets Nerlynx, received approval from the U.S. Food and Drug Administration (FDA) to include…
About Cancer
Cancer, also called malignancy, is an abnormal growth of cells with the potential to invade or spread to surrounding tissues and structures found within the body. There are more than 100 types of cancer. A few examples include breast cancer, skin cancer, lung cancer, colon cancer, prostate cancer, and lymphoma. According to the American Cancer Society, 4 out of 10 people will be diagnosed with some form of cancer in their lifetime. Cancer prevalence has given rise to multiple medical specialties focused on symptom management and disease management. Current treatment options depending on the form of cancer include chemotherapy, radiation, blood or bone marrow transfusions, and/or surgery. Lifetime prognosis of cancer mortality is dependent on the type of cancer and is heavily conditional to early detection.
Conditions
Cancer News
FDA Approves Zejula as Late-Line Treatment for Recurrent Ovarian Cancer Patients
This post was originally published on this site The U.S. Food and Drug Administration (FDA) has approved Zejula (niraparib) as a late-line treatment for women with advanced ovarian, fallopian tube, or primary peritoneal cancer who have tumors defective in DNA repair, a status termed “homologous recombination deficiency” (HRD), and have received at least three prior courses of…
CHMP Recommends Darzalex Triple Combo for Some Newly Diagnosed Multiple Myeloma Patients in EU
This post was originally published on this site The European Medicines Agency (EMA) has recommended that Darzalex (daratumumab) be approved in Europe, in combination with Revlimid (lenalidomide) and dexamethasone, as a first-line treatment for multiple myeloma patients who are ineligible for autologous stem cell transplant (ASCT). Janssen announced the positive opinion by the EMA’s Committee for Medicinal Products for Human Use (CHMP) on…
Durable Responses Seen to ME-401 in Advanced Follicular Lymphoma and CLL/SLL Patients in Ongoing Trial
This post was originally published on this site MEI Pharma’s experimental compound ME-401 reduced tumor burden in 78% of patients with relapsed or refractory follicular lymphoma and in 89% of those with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) in an ongoing Phase 1b trial, the company announced. Responses were durable, updated…
Blincyto Increases Survival of ALL Children, Adolescents After First Relapse, Phase 3 Trials Show
This post was originally published on this site Blincyto (blinatumomab) increases overall survival and disease-free survival in children and adolescents with B-cell acute lymphoblastic leukemia (ALL) who already had their first relapse, data from Phase 3 trials show. Blincyto, developed by Amgen, is an antibody that binds to CD19, a protein found on the surface of…
Bempegaldesleukin-Opdivo Combo Leads to Prolonged Responses in TNBC Patients, Phase 1/2 Trial Shows
This post was originally published on this site Bempegaldesleukin (bempeg, NKTR-214) in combination with Opdivo (nivolumab) leads to prolonged treatment responses in women with advanced or metastatic triple-negative breast cancer (TNBC), a Phase 1/2 trial shows. The findings were presented in a poster titled, “Clinical activity of BEMPEG plus NIVO observed in metastatic TNBC: preliminary…
Prostate Cancer Patients May Safely Skip Radiation Therapy After Surgery, Phase 3 Trial Shows
This post was originally published on this site Men with prostate cancer who undergo surgery have similar long-term outcomes whether they receive radiation therapy shortly after the surgery or only when signs of disease recurrence appear, suggesting that some may be spared the radiation treatment, a Phase 3 clinical trial shows. Findings from the trial…
Follicular Lymphoma Patients Being Recruited for Phase 2 Trial of Aliqopa-Rituximab Combo
This post was originally published on this site A Phase 2 clinical trial is recruiting patients with untreated follicular lymphoma — the most common type of non-Hodgkin’s lymphoma — to study a combination of Aliqopa (copanlisib) and rituximab. The trial (NCT03789240) will be conducted at the National Institutes of Health Clinical Center, in Maryland, under the leadership…
CHMP Favors Keytruda Regimens to Treat Recurrent Head and Neck Cancers
This post was originally published on this site The Committee for Medicinal Products for Human Use (CHMP), a branch of the European Medicines Agency (EMA), has recommended that two regimens of Keytruda (pembrolizumab) be approved in Europe for first-line treatment of metastatic or inoperable recurrent head and neck squamous cell carcinoma (HNSCC). The CHMP recommends that…
Daiichi Sankyo Files New Drug Application for DS-8201 in Japan
This post was originally published on this site Daiichi Sankyo has submitted an application to Japanese regulatory authorities asking that its investigational therapy trastuzumab deruxtecan (DS-8201) be approved as a treatment for people with HER2-positive metastatic breast cancer. The New Drug Application (NDA) is based on results from the multi-center, randomized, open-label DESTINY-Breast01 Phase 2…
FDA Grants Breakthrough Device Designation to IsoPSA Blood Test for Early Prostate Cancer Diagnosis
This post was originally published on this site The U.S. Food and Drug Administration (FDA) has granted breakthrough device designation to Cleveland Diagnostics’ IsoPSA, a minimally invasive blood test for early detection of prostate cancer. The IsoPSA test works by identifying cancer-related structural changes in a key protein. The breakthrough device designation is awarded to…
New Microscope Technique Improves Metastasis Detection in Ovarian Cancer Patients
This post was originally published on this site A newly developed imaging approach that combines laser microscopy with computational analysis may make it easier to spot ovarian cancer cells that have spread to other organs, called metastasis, a study found. The new technique was described in a paper, titled “Two-photon images reveal unique texture features…